Easley, Justin T <br/><br/>
AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.  [electronic resource] 

 -  Physiological reports  10 2016 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2051-817X 
<br/><br/><label>Standard No.: </label>10.14814/phy2.12990  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Anti-Inflammatory Agents, Non-Steroidal--administration & dosage<br/>Aspirin--administration & dosage<br/>Combined Modality Therapy--methods<br/>Dexamethasone--administration & dosage<br/>Docosahexaenoic Acids--administration & dosage<br/>Glucocorticoids--administration & dosage<br/>Inflammation--metabolism<br/>Rats<br/>Receptors, Lipoxin--drug effects<br/>Salivary Glands--cytology<br/>Signal Transduction--physiology<br/>Sjogren's Syndrome--drug therapy<br/>Tumor Necrosis Factor-alpha--drug effects